5 Best Biotech Stocks Under $10 to Buy

2. Fortrea Holdings Inc. (NASDAQ:FTRE)

Number of Hedge Fund Holders: 35 

Stock Price as of Last Close on April 10: $9.18

Fortrea Holdings Inc. (NASDAQ:FTRE) is among the best biotech stocks.

TheFly reported on April that Evercore ISI cut FTRE price target to $14 from $25 while keeping an Outperform rating. The change was part of a broader Q1 healthcare technology and distribution update, where the firm adjusted models and tactical lists across its coverage. The revision reflects updated near-term assumptions used in its analysis. Despite the lower target, the firm maintained a positive rating on the shares within its sector outlook.

On April 7, Fortrea Holdings Inc. (NASDAQ:FTRE) introduced Fortrea Intelligent Technology (FIT), a new suite of digital and AI-enabled clinical trial solutions aimed at improving efficiency and oversight in study execution. The platform integrates workflow automation, data-driven analytics, and AI-supported tools to enhance decision-making and trial management across sponsors, sites, and internal teams.

FIT expands on FTRE’s existing Xcellerate system and introduces upgraded capabilities across clinical development, clinical pharmacology, and medical device research. The offering is structured around lifecycle tools to speed trial execution, foresight tools for predictive insights, and companion tools designed to improve team productivity. The system is available through full-service and functional service models, with select components offered as SaaS, and is intended to support faster, more reliable, and higher-quality clinical trial delivery.

Fortrea Holdings Inc. (NASDAQ:FTRE) is a global contract research organization (CRO) providing clinical trial management, laboratory services, and drug development support. It helps pharmaceutical, biotech, and medical device companies bring therapies to market through outsourced research and clinical development services.